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Abstract
TREK-1 potassium channels are involved in a number of physiopathological processes such as neuroprotection, pain and
depression. Molecules able to open or to block these channels can be clinically important. Having a cell model for screening
such molecules is of particular interest. Here, we describe the development of the first available cell line that constituvely
expresses the TREK-1 channel. The TREK-1 channel expressed by the h-TREK-1/HEK cell line has conserved all its modulation
properties. It is opened by stretch, pH, polyunsaturated fatty acids and by the neuroprotective molecule, riluzole and it is
blocked by spadin or fluoxetine. We also demonstrate that the h-TREK-1/HEK cell line is protected against ischemia by using
the oxygen-glucose deprivation model.
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+) channels are important in brain and cardiovas-
cular diseases both as drug targets and as a cause of underlying
pathology. In mammalian excitable cells, their opening results in an
inhibitory hyperpolarization, while their closing induces an
excitatory depolarization. The therapeutic potential of K
+ channels
as drug targets in medicine is widely recognized, and is an area of
active ongoing research. To date, the class III antiarrhythmics, the
sulfonylureas used in diabetes mellitus are K
+ channel inhibitors,
and some vasodilators such as nicorandil are K
+ channel openers.
Among the large K
+ channel class, the most recently identified
family, is that of the two-pore-domain K
+ channels (K2P) with
four transmembrane segments and two pore-forming P loops [1].
These channels set the membrane potential towards the K
+
equilibrium potential [1,2]. They can be found in excitable or in
non-excitable cells. Many K2P are polymodal and respond to a
wide range of different regulatory inputs. Rapidly, several K2P
channels were identified to be involved in a great diversity of
functional roles and responsible for important diseases. TASK-1
(KCNK-3) plays an important role in potassium dependent
apoptosis [3] and in central nervous system inflammation [4].
Mutations in the gene of TASK-3 (KCNK9) cause a syndrome of
mental retardation [5]. Double TASK-1/TASK-3 deletion in
mice also causes primary hyperaldosteronism [6]. TRESK-1
(KCNK18) was recently shown to be involved in pain and
migraine [7]. TRAAK (KCNK4) alone or in association with
TREK-1 (KCNK2) controls thermal responses of both capsaicin-
sensitive and capsaicin-insensitive sensory neurons [8,9].
The TREK-1 channel is the most extensively studied of the
K2P channels [1,2]. This stretch activated channel is widely
expressed in the brain where it is abundant in regions such as
putamen, caudate nucleus, prefrontal cortex, hypothalamus,
hippocampus and dorsal raphe, cerebral structures strongly
involved in depression [10-12]. TREK-1 is also present in the
dorsal root ganglia (DRG) where it is colocalized with transient
receptor potential (TRP) channels, that are involved in thermo-
sensation [8,9]. The TREK-1 channel is also expressed in
peripheral tissues like smooth muscles of the gastrointestinal tract
or the prostate [11,12,13]. In the cardiovascular system,
expression of this channel has been reported in mesenteric,
pulmonary and basilar arteries [14,15] as well as in skin
microvessels [16]. In the heart, it has been identified in rat left
and right ventricles, atria and septum, and in ventricular myocytes
[17,18] but not in the human myocardium. Pharmacologically,
TREK-1 is insensitive to all the ‘‘classical’’ K
+ channel blockers
such as 4-AP (4-aminopyridine) or TEA (triethylammonium).
Importantly, the complex gating properties of TREK-1 and its
modulation by numerous chemical and physical physiological
stimuli suits it well to a role in regulating the membrane potential
and excitability in various cell types under a range of physiological
and pathological situations. This channel is opened by intracellular
acidosis, increasing temperatures, phospholipids, the neuroprotec-
tive riluzole, volatile and gaseous anesthetics and membrane
stretch [19–24]. TREK-1 is blocked by the stimulation of both
Gq- and Gs-coupled membrane receptors. Interestingly, antide-
pressant selective serotonin reuptake inhibitors (SSRIs) induce a
potent inhibition of this channel [25,26]. These particular ways of
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mice for TREK-1 (TREK-1
2/2) has allowed the demonstration
that TREK-1 channels play a key role in the cellular mechanisms
of anaesthesia
18, neuroprotection [19,27], pain [8,9] and
depression [25,28]. TREK-1
2/2 mice are less sensitive to volatile
anesthetic such as chloroform, halothane, isoflurane or desflurane
than wild type mice. Gaseous anesthetics such as xenon, nitrous
oxide and cyclopropane activate TREK-1 [24]. Polyunsaturated
fatty acids (PUFAs) such as Arachidonic acid (AA), alpha-linolenic
acid (ALA), docosahexaenoic acid (DHA) or lysophospholipids
(LP) such as lysophosphatidylcholine (LPC) also activate TREK-1
channels and are neuroprotective against both ischemia and
seizures induced by kainate injections [22,29]. In mice, the
deletion of the kcnk2 gene results in an increased sensitivity to both
ischemia and epilepsy [22]. TREK-1 channels can be opened by
painful stimulations like pressure or heat. TREK-1
2/2 mice are
more sensitive than wild type mice to pain induced by heat or
mechanical stimuli [8]. TREK-1 channels were reported to be
very important in mood regulation. In five behavioral tests TREK-
1
2/2 mice display a depression resistant phenotype [25]. Thus, it
has been hypothesized that a TREK-1 blocker could be a potent
antidepressant molecule. This hypothesis was validated by the
discovery of spadin, that is a sortilin derived peptide and that
specifically blocks TREK-1 channels [28,30]. Mice treated with
spadin behave similarly to TREK-1
2/2 or fluoxetine-treated
mice. Consequently, TREK-1 channels have become very
attractive molecular and pharmacological targets for the develop-
ment of new molecules with neuroprotective effects or the design
of new drugs for treating pain or mood disorders like depression.
Until now, there are no available cell lines to easily screen such
molecules. TREK-1 channels have to be transfected into regular
cell lines like COS-7, CHO and HEK293. For rapid and efficient
screenings, these techniques raise different problems such as the
yield of transfection and the level of expression. To avoid these
difficulties we developed a HEK293 clone, that we called h-
TREK-1/HEK which stably expresses the TREK-1 channel.
When compared to the native channel, the TREK-1 channel
expressed in the h-TREK-1/HEK clone conserves the sensitivity
to its known activators such as stretch, polyunsaturated fatty acids,
internal pH decrease and riluzole, and to its blockers such as
fluoxetine and spadin. Because hypoxia plays a key role during
ischemia, we highlighted the potent role of the TREK-1 channel




A vector expressing h-TREK-1 (pIRES2-eGFP) was transfected
into HEK-293 cells in the presence of 1.5 mg/ml Geneticin
(G418). After three or four weeks of culture, G418 resistant clones
were isolated and reseeded in the same G418 medium (0.5 mg/
mL instead of 1.5 mg/ml). At this stage, all clones were
electrophysiologically tested after 48 h of culture and only clones
where each single cell expressed the TREK-1 channel were
retained (positive clone). Each positive clone was checked after
each round of culture. After 14 rounds of culture, we did not
observe variations either in the TREK-1 current expression or in
the EGFP expression (Figure 1A,B). The TREK-1 channel
expression was also measured by q-PCR. Results revealed a large
increase in the TREK-1 mRNA expression in the h-TREK-1/
HEK cells (Figure 1C).
To validate the selected clone we studied the modulation of the
TREK-1 channel activity by applying variations of membrane
stretch or internal pH values, current activators (PUFAs, riluzole)
or specific blockers of TREK-1(spadin, fluoxetine). We also
confirmed the ability of TREK-1 to bind
125I-spadin.
Mechanoactivation
Patches were stimulated with negative pressure pulses, from 0 to
260 mmHg in 210 mmHg increment. No current increases were
observed in native HEK cells either in the cell attached (C.A.)
(Figure 2A) or in the Inside-Out (I.O.) (Figure 2C) patch
configurations. With the h-TREK-1/HEK clone in C.A. mode
the current regularly increased with a hyperbolic pattern from
14.561.5 pA to 167.14641.8 pA when the pressure decreased
from 0 mm Hg to 260 mm Hg (Figure 2A, B). In the I. O. mode
we observed a sigmoı ¨dal increase with a plateau value around
250 mm Hg. The maximum current was 542.76161.9 pA at
260 mm Hg (Figure 2C,D). Differences in current values were
expected because in the C.A. mode the cytoskeleton induced an
inhibitory effect on TREK-1 current. The cytoskeleton effect
Figure 1. GFP expression and functional h-TREK-1 channel activity on h-TREK-1/HEK cells. A) Typical pictures of cells observed in
transmission and in fluorescence at round three of cell culture. Functional channel activity was evaluated by current activation with 10 mM AA. B)
Typical pictures of cells observed in transmission and in fluorescence at round fourteenth of cell culture. Functional channel activity was evaluated by
current activation with 10 mM AA. C) Real time q-PCR. Levels of TREK-1 or sortlin expression were normalized with the cyclophillin D expression.
doi:10.1371/journal.pone.0025602.g001
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differences observed in the current patterns (Figure 2B and
Figure 2D).
Sensitivity to internal pH
Lowering the internal pH changes the mechanosensitive
TREK-1 channel into a constitutive leak channel [31]. In the
I.O. patch configuration from h-TREK-1/HEK clone, the
TREK-1 current increased with the acidification from pH 7.2
to pH 5.2. Current values at 0 mV were 81.6618.1 pA,
294.8651.6 pA and 543.26116.7 pA, at pH values of 7.2, 6.2,
and 5.2, respectively (Figure 2E,F). At the same pH values,
currents of HEK were 12.360.4 pA, 12.860 . 2p Aa n d1 2 . 9 60.3
pA, respectively (Figure 2F). These values were reversible
because after a wash with the bath solution the current value
returned to the value measured at pH 7.2, 79.2614.4 pA and
11.960.7 pA for h-TREK-1/HEK and HEK, respectively
(Figure 2E,F).
All the measurements of the following experiments described
below were performed in the presence of a cocktail of potassium
channel inhibitors which did not affect TREK-1 channel activity.
Activation of TREK-1 by polyunsaturated fatty acids
Polyunsaturated fatty acids (PUFAs) like arachidonic acid (AA),
docosahexaenoic acid (DHA) or alpha- linolenic acid (ALA) have
the ability to reversibly activate the TREK-1 channel. These
effects have been demonstrated to be direct on the channel [32].
Thus, we measured their effects on the TREK-1 channel
expressed by the h-TREK-1/HEK cell line. The three PUFAs
were able to largely increase the TREK-1 activity. Current
densities measured at 0 mV in the presence of K
+ blockers or in
the presence of K
+ blockers + PUFA were 6065.9 pA/pF versus
306.2621.7, 159.9642.0 pA/pF versus 583.76113.1 pA/pF and
131.8625.0 pApF versus 467.06114.9 pA/pF for AA, DHA and
ALA, respectively (Figure 3A–C).
Activation of TREK-1 by the neuroprotective molecule
riluzole
Riluzole is an important neuroprotective molecule with
anticonvulsant and anti-ischemic properties [23,33–35]. Riluzole
has been described to induce a transient activation measured 30 s
after drug application followed by an inhibition measured at 90 s
[33]. These biphasic effects were also present with the TREK-1
Figure 2. Stretch and pH activation of h-TREK-1 current in cell attached (C.A.) and in inside out (I.O.) patch clamp configurations.
Currents were recorded by application of negative pressure and by internal acidification. A, B) Current/pressure relationship and typical current
traces obtained on h-TREK-1/HEK cells (closed circle, n=30) and on HEK cells (closed square, n=5) in cell-attached patch clamp configuration. C, D)
Current/pressure relationship and typical current traces obtained on h-TREK-1/HEK cells (closed circle, n=30) and on HEK cells (closed square, n=4)i n
inside-out patch clamp configuration. Inset: negative pressure step protocol, increase 210 mmHg. E, F) Current/potential curves and corresponding
histograms obtained after internal acidification on h-TREK-1/HEK cells (n=8) and on HEK cells (n=3).
doi:10.1371/journal.pone.0025602.g002
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Current density values were of 37.466.4 pA/pF in the presence of
K
+ blocker cocktail alone and were increased to 161.8640.2 pA/
pF after 30 s in the presence of 100 mM riluzole and returned to
60.1611.6 pA/pF after 90 s (Figure 3D,E).
Inhibition of TREK-1 by spadin and fluoxetine
TREK-1 channels play a key role in mechanisms of depression
[25]. Recently, we demonstrated that TREK-1 channels are
inhibited by spadin, a peptide that represents a new concept in
antidepressant drug design [28]. Here, we showed that spadin
blocked TREK-1 current exactly as it did for the transiently
transfected TREK-1 channels (Figure 4A–C). For example,
100 nM spadin inhibited 70% of the TREK-1 current measured
at 0 mV (Figure 4A). The membrane potential did not
significantly affect the ability of spadin to inhibit the TREK-1
channel (Figure 4A inset). The dose for inhibiting 50% of the
TREK-1 channel activity (IC50) was 56.3960.01 nM (Figure 4B).
It was previously shown that TREK-1 channels can be directly
blocked by antidepressant drugs such as Serotonin Selective
Reuptake Inhibitors (SSRIs) like fluoxetine [26]. TREK-1
channels expressed by the h-TREK-1/HEK cell line were
inhibited by fluoxetine (Figure 4D–F). 10 mM of fluoxetine
inhibited 67% of the TREK-1 current measured at 0 mV
(Figure 4D). Here again, the membrane potential did not alter
the inhibiting ability of fluoxetine (Figure 4D inset). The IC50 for
fluoxetine was 6.1860.69 mM (Figure 4E). Additionally, spadin
and fluoxetine prevented the channel activation by riluzole
(Figure 4G–J). Current density values were 40.569.8 pA/pF in
the presence of the K
+ blocker cocktail alone and were not
significantly modified by 100 mM of riluzole in the presence of
100 nM of spadin, 49.7611.8 pA/pF (Figure 4G,H). The same
pattern was observed with fluoxetine, 27.4610.3 pA/pF in the
presence of the K
+ blocker cocktail alone and 33.566.5 pA/pF in
the presence of 100 mM of riluzole and 10 mM of fluoxetine
(Figure 4I,J).
Binding experiments
We previously determined that iodinated spadin was able to
bind on TREK-1 channels [28]. In order to distinguish the
contribution of TREK-1 channels and sortilin for the total
binding, we performed competition experiments on intact cells
(TREK-1 and sortilin) and plasma membrane preparations
(homogenate, only TREK-1) from h-TREK-1/HEK cells. As
previously reported [28], we observed that there was two binding
sites on whole cells with apparent K0.5 of 10
26 M and 10
210 M
(Figure 5A) The low affinity binding sites were also present on
HEK cells (Figure 5A) and disappeared in homogenate prepara-
tions indicating that they correspond to the sortilin receptor. The
high affinity binding sites, that were absent in HEK wild type cells,
were due to the presence of TREK-1 channels (Figure 5B).
Colocalization between TREK-1 channel and Sortilin
receptor
HEK cells constitutively expressed the sortilin receptor which
was not increased by the stable expression of h-TREK-1 channels
Figure 3. Pharmacological activation of h-TREK-1 current in whole cell patch clamp configuration. Currents were recorded in the
presence of a cocktail of potassium channel inhibitors (K
+ blockers). A) Current/potential curves and corresponding current traces obtained before
(closed circle) and after (open circle) current activation by AA 10 mM (n=118). B) Current/potential curves and corresponding current traces obtained
before (closed circle) and after (open circle) current activation by DHA 10 mM (n=10). C) Current/potential curves and corresponding current traces
obtained before (closed circle) and after (open circle) current activation by ALA 10 mM (n=10). D) Current/potential curves and corresponding
current traces obtained before (closed circle) and after current activation by riluzole 100 mM (n=12) perfused during 30 s (open circle) or 90 s (closed
triangle). Each pharmacological activator was tested on HEK-293 native cells (n=10) and current/potential curves were shown in the inset of each
curve. E) Current density values measured at 0 mV after different times of perfusion of 100 mM riluzole (n=10 at each time value).
doi:10.1371/journal.pone.0025602.g003
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an addressing partner to the plasma membrane for TREK-1
channels [28]. As expected, we showed by immunolabelling that
both proteins were co-localized at the plasma membrane level in
the h-TREK-1/HEK cell line (Figure 5C).
Protective effects of TREK-1 channel against hypoxia
We studied the protective role of TREK-1 channels by using the
OGD protocol, which is considered as the best reliable in vitro
model of ischemia [36,37]. OGD consists in a glucose and oxygen
deprivation, 1.2% instead of 5% in normal conditions. HEK and
h-TREK-1/HEK cells were grown in different conditions and,
after two hours of OGD, the number of cells which survived was
counted in 9 areas of the Petri dish, these 9 areas were selected
randomly by a computer. It clearly appeared that TREK-1
expression increased the survival, 934617 versus 383619 for h-
TREK-1/HEK and HEK cells, respectively (Figure 6, conditions
1 and 2). Application of 10 mM AA, an activator of TREK-1
induced an increase of cell survival (Figure 6, condition 3). For the
h-TREK-1/HEK cell line treated with 10 or 50 mM spadin the
number of survival cells is close to that of HEK treated with
10 mM spadin (Figure 6, conditions 4, 5 and 6). The expression of
the sortilin receptor, which increased the number of TREK-1
channels at the plasma membrane induced a higher increase in the
survival (1124615 compared to 934617: conditions 7 and 2). This
sortilin-induced increase was prevented by a 10 mM spadin
treatment (Figure 6, condition 8). All these results showed that
the presence of TREK-1 in the stable HEK cell line is protective
against ischemia and that spadin, the specific inhibitor of TREK-1
potently reverses this effect.
Discussion
The generation of TREK-1 knock-out mice (KCNK2
2/2) has
enabled direct evaluation of the contribution of these channels to
native currents. More importantly, this mouse strain has been used
to examine proposed roles for TREK-1 channels in physiological
functions or drug action. Because, there are no tissues or cell lines
Figure 4. Pharmacological inhibition of h-TREK-1 current in whole cell patch clamp configuration by spadin (n=12 for each dose)
and fluoxetine (n=12 for each dose). Currents were recorded in the presence of a cocktail of potassium channel inhibitors (K
+ blockers). The
inhibition was obtained after the pre-activation of the current by 10 mM AA. A) Current/potential curves obtained in presence of K
+ blockers (closed
circles), K
+ blockers + AA (open circles) and K
+ blockers + AA + spadin 1 mM (closed triangles). The absence of voltage dependence of spadin
inhibition (100 nM) was shown in the inset. B) Spadin dose dependent inhibition at 0 mV potential. C) Typical traces of hTREK-1 current pre-activated
by 10 mM AA and inhibited by 1 mM spadin. D) Current/potential curves obtained in the presence of K
+ blockers (closed circles), K
+ blockers + 10 mM
AA (open circles) and K
+ blockers + 10 mMA A+ 30 mM fluoxetine (closed triangles). The absence of voltage dependence of fluoxetine inhibition
(10 mM) was shown in the inset. E) Fluoxetine dose-dependent inhibition at 0 mV potential. F) Typical traces of h-TREK-1 current pre-activated by
10 mM AA and inhibited by 30 mM fluoxetine. G, H) Current/potential curves and representative traces of spadin inhibition (1 mM) on 100 mM riluzole
activated hTREK-1 current (n=10). I, J) Current/potential curves and representative traces of fluoxetine inhibition (30 mM) on 100 mM riluzole
activated hTREK-1 current (n=10).
doi:10.1371/journal.pone.0025602.g004
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the TREK-1 channel have been conducted in transient transfected
cells. This technique poses several problems including the number
of cells that are transfected, the level of expression of the channel
in the transfected cells and the time during which the cells are
available for measurements. These problems render difficult and
longer large scale screenings of compounds interacting with the
TREK-1 channel. Here, we developed a cell line, the h-TREK-1/
HEK that allows avoiding all these problems. At least up to 14
rounds of culture, each single cell expresses the channel at a similar
level and the culture can be still maintained for several days or
weeks. The generation of the h-TREK-1/HEK cell line, which
stably expresses a functional h-TREK-1 channel with all its
regulation pathways represents a highly efficient screening method
for the development of drugs modulating the TREK-1 channel.
This is of particular importance because TREK-1 channels are
involved in several physiopathological processes such as pain
[8,9,38], neuroprotection [19,22,23,33] and mood disorders
[25,28]. Thus, molecules or drugs able to activate TREK-1 could
be potentially used for treating pain or as neuroprotective
molecules against stroke or epilepsy. Conversely, molecules or
drugs able to inhibit this channel will be useful for treating
depression. Thanks to the use of the h-TREK-1/HEK cell line,
TREK-1 modulators (openers and blockers) will be now screened
more rapidly and more efficiently. Generally, cell lines that stably
express ionic channels are currently used for pharmacological
studies such as HERG and KVLQT1 channels, the two most
important repolarizing cardiac currents responsible for long QT
syndrome and Torsades de Pointes [39,40–42].
Such a method targeting the TREK-1 channel will potentially
allow the discovery and development of new drugs against
neurological disorders such as depression, epilepsy and ischemia.
It will be also crucial to identify new anesthetics and analgesic
molecules. Activation of TREK-1 channels by volatile and gaseous
anesthetics [24] may also be important for their anesthetic activity
in vivo. TREK-1 channels also contribute to temperature and
mechanical pain sensation. Single C-fibers recordings in skin-
nerve preparations from TREK-1 KO mice revealed heightened
sensitivity to raised temperature over a range where TREK-1
channels are strongly activated (30–45uC). Enhanced sensitivity to
mechanical stimuli is also observed in TREK-1 deficient mice,
while increased pain sensitivity associated with inflammation is
reduced in these mice. These results indicate that drugs targeting
TREK-1 channels obtained by screening with the h-TREK-1/
HEK cell line could be used in pain treatment. TREK-1 activators
might increase threshold for thermal and/or mechanical pain,
whereas blockers of TREK-1 could decrease hyperalgesia
associated with inflammation.
TREK-1 is resistant to hypoxia and opens during chemical
ischemia [43,44]. Polyunsaturated fatty acids, riluzole and
lysophospholipids, that are potent openers of TREK-1
[31,33,45] protect rodent brain against global, focal and spinal
ischemia and induce ischemic and epileptic tolerance [19,34,46–
50]. Ischemia results from an interruption in the arterial blood
supply to the brain, resulting in restricted oxygen and glucose
supply to tissue distal to the obstruction. During brain ischemia,
endogenous AA is released, intracellular pH falls and neurons
swell. These alterations contribute to opening of TREK-1
channels leading to a hyperpolarisation that lowers intracellular
calcium and limits glutamate excitotoxicity. The crucial role of
TREK-1 in PUFA- and LP-induced neuroprotection against
ischemia was further indicated by the fact that TREK-1 deficient
Figure 5.
125I-spadin competition and immunolabeling experiments on h-TREK-1/HEK cells and HEK cells. A, B)
125I-spadin competition
experiments performed on whole cells (n=3) and on plasma membrane homogenate (n=3). c) Immunolabelling of h-TREK-1 (green labeling) and
sortilin (red labeling) proteins. The co-localization of the two proteins is shown on the Merge picture.
doi:10.1371/journal.pone.0025602.g005
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the neuroprotection by PUFAs and LPs disappears in the KO
mice [22].In vitro models of ischemia, although isolated from the
effects of cardiovascular system, aim specifically to mimic the
rapid depletion of oxygen and glucose seen under ischemic
conditions in vivo. Thus, such models of oxygen and glucose
deprivation (OGD) allow specific mechanistic processes to be
investigated in a drug-naı ¨ve environment as well as the screening
of potential neuroprotective molecules. In this work, we applied
the OGD model on the h-TREK-1/HEK cell line. Clearly, the
h-TREK-1/HEK cell line, where all single cells express the
TREK-1 channel is protected against the deleterious neuronal
damage induced by OGD. Application of AA enhances the
neuroprotection induced by the presence of TREK-1 in the cell
line, which is prevented by spadin, the specific blocker of TREK-
1. All these results demonstrate that TREK-1 channels are
resistant to hypoxia. The h-TREK-1/HEK cell line has allowed
the first direct demonstration of the involvement of TREK-1
channels in the protection against ischemia. In addition, this work
proves that the h-TREK-1/HEK cell line represents a reliable
and efficient tool to investigate different strategies of neuropro-
tection targeting TREK-1. In addition to its function on neuronal
activity, it is also known that activation of TREK-1 channels
enhances collateral blood flow during cerebral ischemia [14].
TREK-1 channels are necessary for receptor-mediated genera-
tion of nitric oxide by vasodilatators such as acetylcholine in
endothelial cells [14,16]. They also contribute directly to
hyperpolarizing and relaxing effects of PUFAs on vascular
smooth muscle [14,16]. The h-TREK-1/HEK cell line might
be very useful for the screening of new vasodilators. Finally, it was
reported that specific TREK-1 antagonists might be useful agents
for the treatment of depression, since the deletion of TREK-1
induces a depression-resistant phenotype. The discovery of spadin
afforded this hypothesis. Spadin develops antidepressant proper-
ties and represents a new concept of antidepressant drug design.
Binding experiments and colocalisation between TREK-1 and
sortilin in the h-TREK-1/HEK cell line are good arguments for
further identification of new TREK-1 partner proteins. This work
also shows that the h-TREK-1/HEK cell line responds to spadin
by inhibiting the TREK-1 channel and highly suggests that it will
be useful to efficiently and rapidly screen analogs of spadin with a
better affinity and stability.
In conclusion, the development of an available cell line that
allows rapid and reproducible large scale and/or high throughput
screenings of molecules interacting with TREK-1 represent a very
powerful tool. It will allow the identification of high-affinity
openers and blockers of TREK-1 that might prove useful for a
range of cardiovascular and neuronal disease states. It is also
expected to yield additional insights into regulation and physio-
logical functions of TREK-1.
Figure 6. Oxygen deprivation glucose experiments (OGD) on h-TREK-1/HEK cells and on HEK cells (A, B). After two hours of OGD in
control conditions or with different treatments, survival cells were fixed, labeled and counted (n=8 for each groups). A) Typical pictures of cells from
each tested condition. B) Histograms of number of survival cells (Tukey test, F7,568=38.65; *** or ### or $$$ p,0.001) c) The different tested
conditions and their corresponding number.
doi:10.1371/journal.pone.0025602.g006
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Cell culture
The coding sequence of the human TREK-1 (kcnk2) gene
(GenBank Acc. No. NM_014217) was cloned into pIRES2-eGFP
vector (Invitrogen, Cergy-Pontoise, France). In order to obtain a
cell line that stably expresses the TREK-1 channel, the plasmid
was transfected (25 ng) into HEK-293 cells (American Type
Culture Collection, Manassas, VA, USA) using the Calcium
Phosphate method as described by the manufacturer protocol in
the presence of 1.5 mg/mL Geneticin (G418) (Invitrogen, Cergy-
Pontoise, France). After 20–30 days of culture in G418 selection
medium, individual colonies of resistant cells were isolated by
using cloning cylinders (Sigma Aldrich, Saint-Quentin Fallavier,
France). For all subsequent cultures the human-TREK-1/
HEK293 (h-TREK-1/HEK) cells were grown in the presence of
0.5 mg/mL G418 in Dulbecco’s modified Eagle’s medium
supplemented with 10% (v/v) heat inactivated fetal bovine serum
containing 1% (v/v) penicillin/streptomycin in an atmosphere of
95% air/5% CO2. Functional expression was validated by
performing electrophysiological measurements on cells seeded 1–
2 days before use on glass coverslips with the same medium but
without G418. Native HEK293 (HEK) cells were grown in
Dulbecco’s modified Eagle’s medium containing 1% (v/v) of
penicillin/streptomycin and Glutamax (Invitrogen, Cergy- Pon-
toise, France) and supplemented with 10% (v/v) heat inactivated
fetal bovine serum in an atmosphere of 95% air/5% CO2.
Real-Time quantitative RT-PCR analysis
Total RNAs from HEK and h-TREK-1/HEK cells were
isolated with the RNA easy mini kit (Qiagen, Les Ulis, France).
5 mg of total RNAs were used for reverse transcription reaction
carried out with the Superscript II reverse transcriptase (Invitro-
gen, Cergy-Pontoise, France) according to the protocol of the
supplier. Real-time PCR analysis (SYBR green mastermix plus,
Eurogentec, Seraing, Belgium) was performed to estimate the level
of expression of TREK-1 and the endogenous reference,
cyclophilin D (CycloD). Real-time PCR assays (triplicate for each
target gene tested) were performed in 96-well plates on an ABI
GenAmp 5700 apparatus. Data were analyzed using the
comparative Ct method where the amount of target was
normalized to the endogenous reference (User bulletin Nu2
Applied Biosystems). Primers used for the different amplicons
were as follows: TREK-1 forward TTTTCCTGGTGGTCG-
TCCTC; TREK-1 reverse GCTGCTCCAATGCCTTGAAC;
CycloD forward GGCTCTTGAAATGGACCCTTC; CycloD
reverse CAGCCAATGCTTGATCATATTCTT.
Electophysiology
Whole cell current recordings. Electrophysiological
experiments were performed on native HEK and h-TREK-1/
HEK- cells seeded at a density of 20,000 cells/35-mm dishes 2
days before testing. TREK-1 current was recorded using the
whole-cell configuration of the patch-clamp technique. Each
current was calculated by using a RK 400 patch clamp amplifier
(Axon Instrument, Sunnyvale, CA, USA), low-pass filtered at
3 kHz and digitized at 10 kHz using a 12-bit analog-to-digital
converter digidata (1322 series, Axon Instrument, Sunnyvale, CA,
USA). Patch clamp pipettes were pulled using vertical puller (PC-
10, Narishige, London, UK) from borosilicate glass capillaries and
had a resistance of 3–5 MV. The bath solution contained (in mM)
150 NaCl, 5 KCl, 3 MgCl2, 1 CaCl2 and 10 HEPES adjusted to
pH 7.4 with NaOH. The pipette solution contained (in mM) 155
KCl, 3 MgCl2, 5 EGTA and 10 HEPES adjusted to pH 7.2 with
KOH. All experiments were performed at room temperature (21–
22uC). TREK-1 currents were measured in the presence of a
cocktail of potassium channel inhibitors (K
+ blockers: 3 mM 4-
aminopyridine (4-AP), 10 mM tetraethylamonium (TEA), 10 mM
glibenclamide, 100 nM apamin and 50 nM charybdotoxin).
Stimulation protocols and data acquisition were carried out
using a microcomputer (Dell Pentium) which used commercial
software and hardware (pClamp 8.2). Cells were clamped at
280 mV and voltage changes were applied by step of 20 mV
(from 2100 to +60 mV). Duration of depolarization pulses were
0.825 ms, and the pulse cycling rate was 5 s. TREK-1 current
amplitudes were calculated at the end of stimulation pulses. Cells
were continuously superfused with a microperfusion system.
Electrophysiological characterization of human TREK-1 current
was obtained by using two channel inhibitors (spadin and
fluoxetine) and four activators (three fatty polyunsaturated
acids: arachidonic acid, AA; alpha- linolenic acid, ALA,
docosahexaenoic acid, DHA, and one benzothiazole: riluzole).
Five concentrations of spadin (0.01; 0.03; 0.1; 0.3 and 1 mM) and
fluoxetine (1; 3; 10; 30 and 100 mM), and one concentration of
AA, ALA, DHA (10 mM) and riluzole (100 mM) were tested on the
TREK-1 current. Current amplitudes were expressed in current
densities. Results are expressed as mean 6 standard error of the
mean (SEM). The calculation of the IC50 value of spadin and
fluoxetine were obtained from dose response curves fitted with a
standard sigmoidal Hill function [(y=Vmax (Xn/kn+ Xn))].
Stretch experiments. Stretch experiments were performed
in both cell attached an inside out patch clamp configurations.
The bath solution contained (in mM) 155 KCl, 3 MgCl2, 5 EGTA,
and 10 HEPES adjusted to pH 7.2 with KOH. The pipette
solution contained (in mM) 150 NaCl, 5 KCl, 2 CaCL2 and 10
HEPES adjusted to pH 7.4 with NaOH. Patch pipettes were of
about 1.5 MV membrane, and patches were stimulated with
negative pressure pulses, from 0 to 260 mmHg in 210 mmHg
increments during 300 ms each 3 s, through the recording
electrode using a pressure-clamp device (ALA High Speed
Pressure Clamp-1 system; ALA-scientific).
pH experiments. These experiments were only performed in
inside-out patch clamp configuration. Ramp protocol was used
from 2120 mV to +50 mV during 550 ms each 3 s. Holding
potential was maintained at 280 mV. For all experiments,
currents were filtered at 1 kHz, digitized at 20 kHz, and
analyzed with pCLAMP9.2 and ORIGIN 6.0 software.
Binding assays
For competition experiments, intact cells or homogenates from
HEK or h-TREK-1/HEK cells were incubated with 0.2 nM
125I-
spadin (200,000 cpm in 250 ml) iodinated and purified as
previously described [28]. Incubations were performed in
50 mM Tris-HCl, pH 7.4 containing 0.1% BSA in the presence
of increasing concentrations of non-radioactive spadin (10
210 to
10
25M). Incubations were ended by addition of 2 ml of ice-cold
binding buffer followed by filtration through cellulose acetate
filters (Sartorius, Go ¨ttingen, Germany) and washing twice with
2 ml of ice-cold buffer. Radioactivity on filters was counted with a
gamma-counter.
TREK-1/NTSR3/Sortilin colocalization experiments
H-TREK-1/HEK cells were first washed for 5 min in PBS,
then fixed with 4% paraformaldehyde in PBS for 20 min at room
temperature. Coverslips were washed twice with PBS, cells were
permeabilized in 0.3% Tween in PBS for 10 min. After 2 hours in
PBS containing 2.5% Horse Serum (HS), cells were labeled with a
goat polyclonal anti-NTSR3/Sortilin (1/100) and a rabbit anti-
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France), for 16 h at 4uC in PBS containing 5% HS. Cells were
washed three times in PBS, then incubated at room temperature in
PBS containing FITC conjugated donkey anti-goat antibody (1/
1000) and a Texas Red conjugated donkey anti-rabbit antibody
(1/1000) in PBS containing 5% HS for 45 min. After two washes
with PBS and one with water, coverslips were mounted on glass
slides with mowiol for confocal microscopy examination.
Oxygen Glucose Deprivation (OGD)
HEK-293 and h-TREK-1/HEK cells were seeded at a density
of 40,000 cells/35-mm dish. OGD experiments were performed
after 2 days of culture [36,37]. After three washouts with glucose
free Earl’s balanced salt solution (BSS), cells were maintained in
the same BSS medium, (140 NaCl, 5.4 KCl, 1.2 CaCl2, 0.9
MgCl2, 0.44 KH2PO4, 4.17 NaHCO3 and 0.34 Na2HPO4 in
mM). Prior to use, BSS was equilibrated with the anaerobic gas
mixture (95% CO2/3.8% N2/1.2 O2) by bubbling for 15 min,
adjusted to pH 7.4 if necessary, and heated to 37uC. Then, cells
were placed for two hours in humidified incubator at 37uCi n
anaerobic gas conditions. After OGD, cells were washed with
phosphate buffered saline solution (PBS, Invitrogen, Cergy-
Pontoise, France) and then cells were fixed with paraformaldehyde
4% (PAF) at 4uC. Cells were washed 3 times with PBS. Then,
nuclei of living cells were labeled by Hoechst during 10 minutes at
4uC. Cells were washed with PBS (63) and labeled cells were
visualized by using a videomicroscope with a Metafluor software.
Cell countings were made automatically by ImageJ software and
results were expressed as mean 6 SEM. OGD was carried out on
native HEK 293 and h-TREK-1/HEK cells with different
treatments: 1/HEK 293 cells were treated in control conditions
or in the presence of spadin (10 mM), 2/h-TREK-1/HEK cells
were treated in control conditions or in the presence of AA
(10 mM), spadin (10 mM) or spadin (50 mM). For two groups, h-
TREK-1/HEK cells were previously transfected (48 hours before
OGD) with 25 ng of pcDNA containing sort gene encoding
neurotensin receptor 3 called sortilin. For these two groups, OGD
was carried out in control conditions or in the presence of spadin
(10 mM).
Statistics
Data were expressed as mean 6 S.E.M. Statistical analysis of
differences between groups was performed by using unpaired t test
or Tukey test. In all analyses, the level of significance was set at
P,0.05 (*), P,0.01 (**) and P,0.001 (***).
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